Crinetics Pharmaceuticals, Inc.

Good day, everyone, and welcome to the Krenetics Pharmaceuticals second quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. You may register to ask a question at any time by pressing the star and 1 on your telephone keypad. You may withdraw yourself from the queue by pressing star 2. Please note, this call may be recorded. I'll be standing by should you need any assistance. It is now my pleasure to turn the program over to Gaia3 DeWalker.

Thank you, operator. Hello, everyone, and welcome to Kinetics Earning Call. Joining me today are Dr. Scott Struthers, Founder and Chief Executive Officer, Dr. Dana Suzuki, Chief Medical and Development Officer, Jim Hazard, Chief Commercial Officer, and Mark Wilson, Chief Financial Officer. Also joining us for the Q&A portion of the call is Dr. Alan Krasner, Chief Endocrinologist. A press release announcing the second quarter 2024 financial results was issued today and is also available on our corporate website. We will be using slides for today's presentation, which can be viewed on the investor relations section of the Kinetics website. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in your SEC filing. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Kinetics SEC filings, including its annual report on Form 10-K. I would also like to specify that the content of this conference call contains time-sensitive information that's accurate only as of the date of this live broadcast, August 8, 2024. Cornettis takes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With that, I'll hand the call over to Scott.

Thank you, Gayathri. Good afternoon, everyone, and thank you for joining us on our second quarter 2024 results call. I'll begin by spending a few moments summarizing our recent accomplishments. Then I'll hand the call over to Dr. Dana Pizzuti, our Chief Medical and Development Officer, who will provide a regulatory update. Jim Hazard, our chief commercial officer, will share our plans to bring our lead candidate Paltus team to patients. And Mark Wilson, our chief financial officer, will wrap up with a thrilling financial update. The second quarter of 2024 was extremely productive for Krenetics. The Endocrine Society annual meeting in June proved to be an impactful meeting for us. We were thrilled to share highly encouraging initial results from the ongoing Phase II studies of our second development candidate, Atumelnat, in both congenital adrenal hyperplasia and Cushing's disease. These unprecedented data were very well received by the endocrinology community. This reinforced our already strong confidence in the potential of Atumelnat to be a best-in-class and first-in-class agent in both indications. Patients need better therapeutic options, and we are committed to realizing AteneoLens' full potential as a revolutionary new treatment paradigm for people suffering from CAH and Cushing's disease. Kinetic's team is working hard to move development of AteneoLens forward in both indications and bring this potential therapy to people around the world.